FTSE MIB
33.849,20 -32,30 (-0,10%) Dow Jones
37.950,05 +174,67 (+0,46%) Nasdaq
15.573,09 -28,41 (-0,18%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
82,99 +0,26 (+0,31%) Bitcoin EUR
60.857,36 +2.352,80 (+4,02%)
Mereo BioPharma Group plc (0A9G.L)
| Chiusura precedente | 2,6650 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 8.637 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,78 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2850 |
| Prossima data utili | 29 mar 2024 - 02 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,38 |
GlobeNewswireUltragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase
- GlobeNewswire
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR) October 13-16, 2023, in Vancouver, British Columbia. Ultragenyx and its collaborators will present late-breaking presentations on new, updated data from the Phase 2 portion of the
GlobeNewswireMereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST. A live audio webcast of the presentation can be accessed through the Investors section of the Company’
